Federated Hermes Inc. Trims Position in ADMA Biologics Inc (NASDAQ:ADMA)

Key Points

• Federated Hermes Inc. has decreased its stock position in ADMA Biologics Inc. by 7.9%, now holding approximately 1.2 million shares valued at nearly $23.9 million.
• Several hedge funds, including Farther Finance Advisors LLC and CIBC Private Wealth Group LLC, have also made significant changes to their positions in ADMA Biologics, indicating a robust interest from institutional investors.
• ADMA Biologics reported earnings that missed estimates, with a 40.2% increase in revenue year-over-year, highlighting a divergence between strong revenue growth and earnings performance.

Federated Hermes Inc. decreased its holdings in shares of ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 7.9% during the first quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,204,127 shares of the biotechnology company's stock after selling 102,809 shares during the quarter. Federated Hermes Inc. owned 0.51% of ADMA Biologics worth $23,890,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of ADMA. Skandinaviska Enskilda Banken AB publ purchased a new stake in shares of ADMA Biologics in the first quarter valued at approximately $35,000. Tsfg LLC acquired a new position in shares of ADMA Biologics during the first quarter worth $51,000. Farther Finance Advisors LLC increased its position in shares of ADMA Biologics by 1,149.1% during the first quarter. Farther Finance Advisors LLC now owns 2,723 shares of the biotechnology company's stock worth $53,000 after purchasing an additional 2,505 shares in the last quarter. GF Fund Management CO. LTD. purchased a new position in shares of ADMA Biologics in the fourth quarter worth about $85,000. Finally, CIBC Private Wealth Group LLC lifted its stake in ADMA Biologics by 137.1% during the 4th quarter. CIBC Private Wealth Group LLC now owns 5,108 shares of the biotechnology company's stock valued at $95,000 after acquiring an additional 2,954 shares during the period. Institutional investors own 75.68% of the company's stock.

Wall Street Analyst Weigh In

ADMA has been the topic of a number of recent analyst reports. Wall Street Zen downgraded shares of ADMA Biologics from a "hold" rating to a "sell" rating in a report on Friday, May 9th. Raymond James Financial boosted their price target on ADMA Biologics from $25.00 to $32.00 and gave the stock a "strong-buy" rating in a research report on Thursday, May 8th.

Insider Activity

In related news, Director Jerrold B. Grossman sold 10,000 shares of the stock in a transaction dated Monday, June 9th. The shares were sold at an average price of $21.31, for a total transaction of $213,100.00. Following the completion of the transaction, the director directly owned 478,194 shares of the company's stock, valued at $10,190,314.14. This represents a 2.05% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Steve Elms sold 194,749 shares of the company's stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $20.24, for a total transaction of $3,941,719.76. Following the transaction, the director owned 87,330 shares in the company, valued at $1,767,559.20. The trade was a 69.04% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 464,621 shares of company stock valued at $9,644,269. Insiders own 3.70% of the company's stock.

ADMA Biologics Stock Up 3.7%

Shares of ADMA stock traded up $0.71 on Monday, reaching $20.04. 767,843 shares of the stock were exchanged, compared to its average volume of 3,052,070. ADMA Biologics Inc has a twelve month low of $10.21 and a twelve month high of $25.67. The company has a market capitalization of $4.78 billion, a price-to-earnings ratio of 23.53 and a beta of 0.38. The company has a current ratio of 6.58, a quick ratio of 3.36 and a debt-to-equity ratio of 0.22. The business's 50 day moving average price is $18.81 and its 200 day moving average price is $18.78.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last announced its earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 EPS for the quarter, missing analysts' consensus estimates of $0.16 by ($0.02). ADMA Biologics had a net margin of 45.01% and a return on equity of 47.16%. The business had revenue of $114.80 million during the quarter, compared to analysts' expectations of $116.40 million. During the same period in the previous year, the company posted $0.08 earnings per share. ADMA Biologics's quarterly revenue was up 40.2% on a year-over-year basis. As a group, sell-side analysts expect that ADMA Biologics Inc will post 0.51 earnings per share for the current fiscal year.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.